empty
 
 
sk
Search
Podpora
Okamžité otvorenie účtu
Obchodná platforma
Vklad / odobratie
Search
Pre začiatočníkov Pre obchodníkov Pre partnerov Dajte si pauzu O InstaForexe
sk
#DHR Return to the list of instruments #DXCM

Currency converter

Dynavax Technologies Corporation
15.49 USD
23 Jan 2026 22:59
Zmena ceny (% chg)
$-0.04
(-0.26%)
Prechádzajúca uzatváracia cena
Prechádzajúca uzatváracia cena

Uzatváracia cena predchádzajúceho dňa.
$15.63
Otváracia cena
Otváracia cena

Cena na ktorej otvoril daný deň.
$15.67
Denné maximum
Denné maximum

Najvyššia cena počas posledného obchodného dňa.
$15.64
Denné minimum
Denné minimum

Najnižšia cena počas posledného obchodného dňa
$15.49
Trhová kapitálizácia
Trhová kapitálizácia

Celková hodnota spoločnosti na akciovom trhu. Vo všeobecnosti sa vypočíta ako násobok počtu akcií v obehu a aktuálnej ceny za jednu akciu.
$15.66
Akcie v obehu
Akcie v obehu

Počet akcií držaných investormi a majiteľmi spoločnosti, okrem tzv. rozrieďujúcich cenných papierov ako sú neodňateľné RSU a neuplatnené opcie.
$15.49
Download archive
Buy
15.49
Sell
15.49
Open the chart in full screen view
Buy
15.49
Sell
15.49
Download archive
Open the chart in full screen view

Dynavax Technologies Corporation. About company

Dynavax Technologies Corporation is a biopharmaceutical company whose core business is the development and production of vaccines.

The company’s main product is a hepatitis B drug. The company also produces vaccines against coronavirus, influenza, plague, and other infectious diseases.

In addition, the company is mainly focused on the production of adjuvants. These substances help vaccines to be better absorbed by the body.

Currently, Dynavax has a market capitalization of $1.37 billion. Last year, the company posted revenues of $438.24 million and a net income of $76.71 million.

Dynavax Technologies Corporation’s shares and what affects their price

Dynavax shares have been trading on the NASDAQ exchange under the DVAX ticker since 2004. The initial price per share stood at $7.50.

Currently, the company’s shares are trading between $10 and $12. During the year, the share price was hovering between $7 and $22. At the same time, the company does not pay dividends to its shareholders.

What to pay attention to when trading the company’s shares:

  • Long-term growth prospects are driven by a large number of innovative developments;
  • The target price for the stock is several times higher than the current one, ranging between $45.5 and $48, according to forecasts;
  • Adjuvant technology is an advantage for the company since these additional substances significantly enhance the effect of the vaccines.

Can't speak right now?
Ask your question in the chat.